Synonyms: deuremidevir | JT001 | Mindavi® | VV-116 | X6 hydrobromide [PMID: 34584244]
VV116 is an approved drug (China NMPA (2023))
Compound class:
Synthetic organic
Comment: VV116 is an orally available, deuterated remdesivir analogue [4-5]. It is a tri-isobutyrate ester prodrug (formulated as the hydrobromide salt) that is converted to an active nucleoside triphosphate (116-NTP) that acts as a viral RNA-dependent RNA polymerase (RdRP) inhibitor. VV116 was developed for antiviral activity against SARS-CoV-2. We drew the chemical structure as represented in Xie et al. (2021) [4].
|
|
References |
1. Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X et al.. (2023)
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med, 388 (5): 406-417. [PMID:36577095] |
2. Fna X, Dai X, Ling Y, Wu L, Tang L, Peng C, Huang C, Liu H, Lu H, Shen X et al.. (2023)
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. Lancet Infectious Diseases, Epub ahead of print. DOI: 10.1016/S1473-3099(23)00577-7 |
3. Qian HJ, Wang Y, Zhang MQ, Xie YC, Wu QQ, Liang LY, Cao Y, Duan HQ, Tian GH, Ma J et al.. (2022)
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin, 43 (12): 3130-3138. [PMID:35296780] |
4. Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, Tian G, Aisa HA, Xu Y, Xiao G et al.. (2021)
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res, 31 (11): 1212-1214. [PMID:34584244] |
5. Zhu KW. (2023)
Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19. ACS Pharmacol Transl Sci, 6 (9): 1306-1309. [PMID:37705591] |